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Available online 18 October 2014Abstract Lmx1a plays a central role in the specification of dopaminergic (DA) neurons, which potentially could be employed
as a key factor for trans-differentiation to DA neurons. In our previous study, we have converted somatic cells directly into
neural stem cell—like cells, namely induced neural stem cells (iNSCs), which further can be differentiated into subtypes of
neurons and glia in vitro. In the present study, we continued to test whether these iNSCs have therapeutic effects when
transplanted into a mouse model of Parkinson's disease (PD), especially when Lmx1a was introduced into these iNSCs under a
Nestin enhancer. iNSCs that over-expressed Lmx1a (iNSC-Lmx1a) gave rise to an increased yield of dopaminergic neurons and
secreted a higher level of dopamine in vitro. When transplanted into mouse models of PD, both groups of mice showed
decreased ipsilateral rotations; yet mice that received iNSC-Lmx1a vs. iNSC-GFP exhibited better recovery. Although few iNSCs
survived 11 weeks after transplantation, the improved motor performance in iNSC-Lmx1a group did correlate with a greater
tyrosine hydroxylase (TH) signal abundance in the lesioned area of striatum, suggesting that iNSCs may have worked through a
non-autonomous manner to enhance the functions of remaining endogenous dopaminergic neurons in brain.
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Induced neural stem cells (iNSCs) are reprogrammed cells
that possess features like bona fide neural stem cells (NSCs).
In 2012, we have reported that mouse somatic cells—sertoli
cells, can be directly converted to iNSCs by introduction of 8
transcription factors (Sheng et al., 2012a), which provides
further evidence that somatic cells can be induced to not
only pluripotent stem cells (PSCs) (Takahashi and Yamanaka,
2006; Takahashi et al., 2007; Yu et al., 2007), mature
neurons (Vierbuchen et al., 2010; Pfisterer et al., 2011;
Caiazzo et al., 2011; Kim et al., 2011), but also to adult stem
cells. The above findings support the concept that the fates
of any two different lineages are interchangeable, given
sufficient and necessary conditions.
In our previous work, we have shown that iNSCs converted
from sertoli cells demonstrate the characteristics of NSCs in
vitro, such as self-renewal, differentiation to neurons and glia,
and similar gene expression profiles, etc. After transplantation
into the native area of neurogenesis—dentate gyrus in adult
mouse brain, iNSCs can survive and further mature to neurons.
However, whether iNSCs have therapeutic efficacy in neuro-
degenerative disease models, for example, Parkinson's disease
(PD), has not been tested yet.
Lmx1a is a key determinant in the specification of
dopaminergic (DA) neurons (Deng et al., 2011; Andersson et
al., 2006). When exogenously expressed in embryonic stem
(ES) cells, LMX1a markedly enhances the efficiency for DA
neuron production (Friling et al., 2009). We thus speculate
that expression of Lmx1a in iNSCs may further increase their
capacity to differentiate to DA neurons. In this study, we aim
to investigate whether iNSCs are safe and/or efficacious in a
mouse PD model, and whether expression of Lmx1a in iNSCs
can further enhance the therapeutic efficacy.Materials and methods
Cell culture
iNSC 1-9, an induced neural stem cell line, trans-differentiated
from sertoli cells from neonatal C57BL/6 mice, has been
described in our previous work (Sheng et al., 2012a). In this
study, iNSC 1-9 was firstly labeled by lentiviral vectors
expressing GFP – FUGW (Addgene, Cambridge, MA), and
then infected with lentiviral vectors pNestin-Lmx1a-2A-BlastR
(pNestin-GFP-2A-BlastR as control) (Fisher Scientific, Pitts-
burgh, PA). After 1 week of selection with 6 μg/ml blasticidin
(Invitrogen, Carlsbad, CA), the surviving cells were replated on
PDL (Sigma-Aldrich, St Louis, MO)/Laminin (Roche, Mannheim,
Germany)-coated plates in N2B27 medium plus 20 ng/ml bFGF
and EGF (both from Peprotech, Rocky Hill, NJ) (Ying et al.,
2003). iNSC 1-9 FUGW pNestin-Lmx1a (iNSC-Lmx1a) and iNSC
1-9 FUGW pNestin-GFP (iNSC-GFP) at passage 27 were used for
karyotype analysis as previously described (Sheng et al., 2012a).
PCR analysis
To confirm the integration of exogenous LMX1A, PCR-
amplification of genomic DNA extracted from iNSC-Lmx1a was
performed using primers specific for the transgenic Lmx1asequences (Forward 5′- CCTCAGTGGATGTTGCCTTTA-3′; Re-
verse 5′- GCTCCCGTTCTTTCTCATAG-3′). Genomic DNA extract-
ed from iNSC-GFP was used as a negative control.
In vitro differentiation
2500 iNSC-Lmx1a or iNSC-GFP cells were plated on PDL/
Laminin-coated 24-well plates. After exposure to 100 nM
SAG (Enzo, Farmingdale, NY), 100 ng/ml FGF-8 (Peprotech)
and 10 ng/ml bFGF (Peprotech) for 2 days, the culture
medium was switched to N2B27 medium with 20 ng/ml BDNF
(Peprotech) and 200 nM ascorbic acid (AA, Sigma-Aldrich).
Immunofluorescence
On the 6th or 14th day of differentiation, iNSC-Lmx1a and
iNSC-GFP cells were washed and fixed by 4% paraformalde-
hyde (Sigma-Aldrich). For immunofluorescence staining,
cells were washed and blocked by 3% donkey serum (Jackson
ImmunoResearch, West Grove, PA) in 0.3% Triton-TBS for
1 h, and incubated with primary antibodies overnight at 4 °C
followed by secondary antibody staining for 2 h at room
temperature. The primary antibodies used were rabbit anti-
tyrosine hydroxylase (TH) (1:1000, Millipore, Billerica, MA),
mouse anti-β III tubulin (Tuj-1) (1:1000, Millipore), mouse
anti-NeuN (1:500, Millipore). The secondary antibodies were
cy3-conjugated donkey anti-rabbit and cy5-conjugated
donkey anti-mouse (both 1:400, Jackson ImmunoResearch).
After nuclear staining with DAPI (Sigma-Aldrich), pictures
were captured by using Leica TCS SP5 confocal microscope
(Leica, Mannheim, Germany).
To compare the capacity to differentiate to DA neurons, 3
or 9 areas on each coverslip were randomly selected for
imaging using the same confocal settings. The proportions of
TH-positive cells were calculated by using Image J software
(National institutes of health, USA).
Animal experiments
All the animal experiments were performed according to the
guidelines for the Care and Use of Laboratory Animals
established by Beijing Association for Laboratory Animal
Science. Unilateral PD mouse model was performed as
previously described (Tabar et al., 2008): eight week old
male C57BL/6 mice were used to establish PD models by
6-hydroxydopamine (6-OHDA, Sigma-Aldrich) administration.
Mice were injected intraperitoneally (i.p.) with 25 mg/kg
desipramine (Sigma-Aldrich) 20 min before anesthetization
with ketamine and Xylazine (Sigma-Aldrich), followed by
injection of 8 μg 6-OHDA in 2 μl saline into the right striatum
(A/P 0.5 mm, M/L −2.3 mm, D/V −3.2 mm). Four weeks after
6-OHDA injection, the mice were i.p. injected with 5 mg/kg
amphetamine (Sigma-Aldrich), and the number of ipsilateral
turns per min (every 5th min in 1 h) was scored. Mice with
stable lesions (N8 turns/min) were selected for transplanta-
tion studies.
Five weeks after 6-OHDA injection, stable PD mice were
randomly divided into 4 groups for engraftment experi-
ments, iNSC-Lmx1a (n = 9), iNSC-GFP (n = 9), sertoli cells
(n = 8), and sham control (n = 7) groups. After being
cultured in N2B27 medium with 100 nM SAG (ENZO),
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8 × 105 iNSC-Lmx1a or iNSC-GFP cells, suspended in 4 μl
transplantation buffer (5 g/l glucose (Sigma-Aldrich) and
100 ng/ml bFGF (Peprotech) in HBSS (Life technologies, Grand
Island, NY)), were injected into the right side of striatum (A/P
0.5 mm, M/L −2.1 mm, D/V −3.4 mm). Sertoli cells isolated
from newborn C57BL/6mice were labeled with FUGW virus and
engrafted into striatum. In sham control group, only buffer was
injected.
Behavioral tests were performed in the 2nd, 4th, 6th and
10th week after transplantation. The results were expressed
as ipsilateral rotations minus contralateral rotations per
min. Videos were recorded by EOS 550D (Canon, Tokyo,
Japan) or DSC-V1 (Sony, Tokyo, Japan) digital camera, and
edited by Final Cut Pro 10.9 (Apple, Cupertino, CA).
Histological analysis
Eleven weeks after transplantation, all mice were perfused
with 4% paraformaldehyde and brains were taken out,
followed by dehydration in 30% sucrose (Sigma-Aldrich) and
sliced coronally at 40 μm thickness. The slices were stained by
using the following primary and secondary antibodies: rabbit
anti-TH (1:500, Millipore), sheep anti-TH (1:500, Millipore),
rat anti-dopamine transporter (DAT) (1:5000, Millipore),
Cy3-conjugated donkey anti-sheep, Cy3-conjugated donkey
anti-rat and Cy5-conjugated donkey anti-rabbit (all 1:200,
Jackson ImmunoResearch).
To evaluate the effect of engrafted cells on the remaining
endogenous DA neurons, we measured the signal intensity of
TH in the right striatum (lesioned and engrafted) relative to
that of the left striatum (no lesion or graft) using the same
confocal settings.
HPLC
In vitro HPLC was performed as previously described (Roy et
al., 2006; Ren et al., 2013). On the 7th and 14th day of
differentiation, 500 μl supernatant from iNSC-Lmx1a, iNSC-
GFP and mouse embryonic fibroblast (MEF) cultures was
collected. After addition of 7 μl perchloric acid (7 N, Sigma-
Aldrich), the supernatant was stored at −80 °C for future use.
For HPLC assay, the supernatant was centrifuged at 12,000 g,
4 °C for 15 min, and 50 μl supernatant was used for examining
levels of dopamine and DOPAC. Each sample was injected
using a 542 automatic injector (Thermo Scientific, Chelms-
ford, MA), and separation was achieved on Zorbax ODS (C-18)
reverse-phase column (150 mm × 4.6 mm, 5 μm) (Agilent,
Santa Clara, CA). Mobile phase containing 90% of 70 mM
sodium acetate, 50 mM citric acid, 0.1 mM EDTA, 0.2 mM
1-octanesulfonic acid sodium salt, and 10% methanol (adjust-
ed to pH 4.1 with NaOH 10 M) (all from Sigma-Aldrich), was
pumped at 0.1 ml/min through the C-18 column connected to
the electrochemical detectors (5600A, Thermo Scientific).
Therewere 3 biological replicates for each group at every time
point and the experiments were repeated twice.
Statistical analysis
The results were expressed as Mean ± SEM. Statistical
analysis was carried out using Graphpad Prism 5 (Graphpadsoftware, La Jolla, CA) or PASW Statistics 18 software (IBM,
Armonk, NY). Three or more groups were compared by using
ANOVA. Pair wise comparisons were made by using Student's
t test. A value of p b 0.05 was considered significant.
Results
Generation of iNSC-Lmx1a
iNSCs 1-9, a cell line that shows similar in vitro and in vivo
functions as naturally existing NSCs, were generated from our
previous work (Sheng et al., 2012a,b). To explore whether
Lmx1a can promote the differentiation of iNSCs into DA
neurons, and enhance its therapeutic efficacy in mouse PD
models, iNSC 1-9 were first labeled with FUGW, a GFP-
expressing lentivirus, followed by infection with pNestin-
Lmx1a lentivirus (or its control virus), which encodes lmx1a
(GFP in control vector) and a blasticidin-resistant gene under
Nestin enhancer (Fig. S1A). To examine whether pNestin-GFP
virus works, normal NSCs were infected with the virus and
stained for nestin and GFP. About 21% of nestin-positive cells
were also GFP-positive (Fig. S1B). After 6 days of selection
with 6 μg/ml blasticidin, many surviving cells were found in
pNestin-Lmx1a and pNestin-GFP groups (Fig. S2A). Surviving
cells showed normal morphology and karyotype, and could
proliferate as monolayer or spheres (Fig. 1A–C). More than
95% of these cells were GFP-positive (Fig. 1D). Exogenous
lmx1a integration was confirmed by genomic PCR analysis
(Fig. S2B). The established cell lines were herein named iNSC-
Lmx1a and iNSC-GFP.
Lmx1a enhances DA neuron production from iNSCs
in vitro
To test the efficiency of DA neuron production, equal numbers
of iNSC-Lmx1a or iNSC-GFP cells were treated for 2 days with
SAG and FGF8, followed by differentiation for 6 or 14 days
with BDNF and AA. TH-positive cells differentiated from
iNSC-Lmx1a and iNSC-GFP cells expressed Tuj-1, and DA neurons
from iNSC-Lmx1a were also positive for NeuN (Fig. S3). On
the 6th or 14th day of differentiation, the proportion of
TH-positive cells was measured. More TH-positive cells were
found in iNSC-Lmx1a group (8.686 ± 1.391% on the 6th day,
15.99 ± 2.104% on the 14th day) vs. iNSC-GFP group
(4.877 ± 0.7151% on the 6th day, 5.271 ± 0.8127% on the
14th day, p b 0.05 on the 6th day, p b 0.001 on the 14th
day, Fig. 2A).
We also examined the concentrations of dopamine and its
metabolite DOPAC in culture supernatant from iNSC-Lmx1a,
iNSC-GFP and MEF cells (Fig. 2B). On the 7th, and 14th day of
differentiation, the concentrations of dopamine and DOPAC
in iNSC-Lmx1a group were higher than those in iNSC-GFP
group, and dopamine and DOPAC were hardly detectable in
MEF supernatant (Fig. 2C).
iNSC-Lmx1a graft improves the
behavioral performance of PD mice
To test the therapeutic effect, iNSC-Lmx1a, iNSC-GFP, sertoli
cells or buffer were introduced into the right side of striatum
Figure 1 Morphology of iNSC-Lmx1a and iNSC-GFP cells. A: Monolayer culture of iNSC-Lmx1a and iNSC-GFP at passage 28. B: Suspension
culture of iNSC-Lmx1a at passage 26. C: iNSC-Lmx1a cells (passage 27) show normal male mouse karyotype. D: iNSC-Lmx1a cells under
fluorescent and bright field. More than 95% (261 of 273) of iNSC-Lmx1a cells are GFP-positive. Scale bars: 200 μm (A and B), and 50 μm
(D).
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All mice survived transplantation and behavioral tests were
performed at 2, 4, 6, and 10 weeks thereafter. At 2 weeks
post-transplantation, the numbers of ipsilateral turns were
significantly reduced in iNSC-Lmx1a and iNSC-GFP groups, but
not in sertoli or buffer groups (Fig. 3B and Table 1). At 4 weeks,
the effects from iNSC-Lmx1a and iNSC-GFP started to
differentiate, and both iNSC groups still showed improved
performance compared to that of control groups (Fig. 3B and
Table 1). At 10 weeks, similar trends existed as at 4 weeks,
with iNSC-GFP groups performing better than buffer group, and
iNSC-Lmx1a better than iNSC-GFP group, suggesting that iNSCs
may have enhanced the nigro-striatum functions by an
autonomous and/or non-autonomous manner (Videos 1 and
2). Interestingly, the numbers of ipsilateral turns showed a
trend of decline even in buffer group (Fig. 3B), probablyreflecting an adaptation to amphetamine treatment and/or
ageing-associated behavioral change.
We next tried to investigate the mechanisms underlying
the behavioral improvement. Eleven weeks after engraft-
ment, the mice were sacrificed and brain slices examined. No
overgrowth of graft was found in any mice; rather, very few
engrafted cells had survived. On each of the 6th consecutively
sliced section, only one or two TH-positive cells were found in
the striatum receiving graft (Fig. 3C), and these TH-positive
cells were positive for GFP and DAT (Fig. S4). Given the small
number of surviving cells, the chance was slim that the
behavioral changes were caused by the differentiation and
integration of incoming iNSCs exerting functions by partici-
pating in the wiring circuits in charge of motor behavior.
The other possibility was that the transplanted cells may
have produced neurotrophic or other soluble factors that
Figure 2 Lmx1a promotes differentiation of iNSCs into DA neurons in vitro. A: The proportion of TH-positive cells in iNSC-Lmx1a
group was significantly higher than that in iNSC-GFP group on the 6th day and 14th day of differentiation. Data were represented as
means ± SEM, n = 18 (6th day of differentiation) and 9 (14th day of differentiation). *, p b 0.05; ***, p b 0.001. B: HPLC
chromatograms of supernatant from MEF, iNSC-GFP or iNSC-Lmx1a culture (24 h incubation) on the 14th day of differentiation. C: DA
and DOPAC concentrations in MEF (gray), iNSC-GFP (red) or iNSC-Lmx1a (blue) culture supernatants (24 h incubation) on the 7th or
14th day of differentiation. Data were represented as means ± SEM in all the figures of this study unless specifically noted, n = 6; ***,
p b 0.001. Scale bars: 40 μm (A).
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Following 6-OHDA injection, the TH signal abundance was
markedly reduced in the dorsal lateral quadrant of the
striatum where lesion was made (Fig. 3D), which may
correlate with the decreased capacity to produce dopamine
and subsequently the compromised motor performance. Wehypothesized that if the transplants worked by augmenting
the nigro-striatum circuit, the TH signals would have been
changed accordingly. Indeed, the relative TH signal abun-
dance in the lesioned quadrant normalized to its counterpart
in the left striatumwas significantly higher in iNSC-GFP group,
andwas even higher in iNSC-Lmx1a group (Fig. 3E).We plotted
6 J. Wu et al.the TH signal abundance against the behavioral results for
each mouse and found a negative correlation between the
ipsilateral turns and TH signals (p = 0.05, R2 = 0.122, Fig. 3F),
indicating that the restored capacity to produce dopamine,
probably resulted from engraftment, may account for the
improved motor behavior.Discussion
In this study, we continued our previous work and examined
the safety and therapeutic efficacy of iNSCs in a mouse PD
model. We found that iNSCs grafts are safe and can improve
the motor performance of PD mice, and expression of Lmx1a
Table 1 Statistical analysis of behavioral tests.
Results of behavioral tests for PD model mice transplanted with iNSC-Lmx1a, iNSC-GFP, sertoli cells or buffer at different time points
were analyzed by two-way ANOVA. P values were showed. NA, non-significant, p N 0.05; *, p b 0.05; **, p b 0.01; ***, p b 0.001.
Weeks after transplantation Groups
iNSC-Lmx1a
VS Buffer
iNSC-Lmx1a
VS Sertoli cells
iNSC-Lmx1a
VS iNSC-GFP
iNSC-GFP
VS Buffer
iNSC-GFP
VS Sertoli cells
Sertoli cells
VS Buffer
−1 NS NS NS NS NS NS
2 *** *** NS *** *** NS
4 *** *** *** ** NS NS
6 ** NS NS NS NS NS
10 *** *** ** * NS NS
NS, non-significant, p N 0.05; *, p b 0.05; **, p b 0.01; ***, p b 0.001.
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tic efficacy. iNSCs have worked probably by restoring the
functions of the endogenous DA neural circuits.
Since the report of iNSCs in 2012 (Sheng et al., 2012a,b),
several other groups have also published studies on iNSCs,
using different starter cells and reprogramming factors (Kim
et al., 2014; Cheng et al., 2014a; Cheng et al., 2014b;
Cheng, 2014; Maucksch et al., 2012; Mitchell et al., 2014;
Zou et al., 2014; Han et al., 2012; Lujan et al., 2012).
Nevertheless, none of those studies had tested the efficacy
of iNSCs in a PD model. To our knowledge, the current study
is the first to provide proof-of-principle that iNSCs exert
therapeutic effects in a PD model. We understand that
sertoli cells which iNSCs were derived from in this study are
not readily accessible in clinics and the number of exogenous
factors may be further reduced using different starter cells;
yet the present study could be a good beginning on the long
way towards clinical applications of iNSCs. Future work is
needed to test if more clinically relevant cells, for example,
iNSCs derived from human fibroblasts or blood cells
converted with fewer factors in a non-integrative manner,
would work in small and large PD animal models.
The iNSCs used in this study had the same genetic
background as the recipient PD mice, and should not elicit
adaptive immune recognition in host (Chen et al., 2011;
Chen and Palmer, 2008). The low survival rate of grafts may
reflect a relatively vulnerable feature of this cell line,
compared to iPSC-derived DA precursor cells (Wernig et al.,
2008), which, however, have an inherent problem of
tumorigenicity. In our previous work (Sheng et al., 2012a;
Sheng et al., 2012b), iNSCs without patterning by SAG and
FGF8 were deposited at the native neurogenic area—dentate
gyrus of naïve mice, and showed a decent survival rate. TheFigure 3 Lmx1a enhances the beneficial effects of iNSC in improvi
abundance in the engrafted striatum. A: Schematic representation of
iNSC-Lmx1a (blue), iNSC-GFP (red), sertoli cells (grey) or buffer (b
transplantation), and 2, 4, 6 and 10 weeks after transplantation. The nu
iNSC-Lmx1a group; n = 9 in iNSC-GFP group; n = 8 in sertoli cell group; a
iNSC-Lmx1a or iNSC-GFP cells were found in the transplantation area in
signal abundance in the dorsal lateral quadrant of striatum relative to it
dorsal lateral quadrant of striatum relative to its contralateral counter
sertoli cell group; and n = 7 in buffer group. *, p b 0.05; ***, p b 0.001.
abundance and the ipsilateral turns at 10 weeks post-transplantation. Af
with the relative TH signal abundance (simple regression, p = 0.05). Scapoor survival observed in the current study may be due to a
lack of supportive niche in striatum, and/or the two-day
patterning period decreasing the capacity of the iNSCs to
survive transplantation.
As expected, mice receiving iNSC-Lmx1a demonstrated
better behavioral results than did mice receiving iNSC-GFP.
In vitro data showed that iNSC-Lmx1a yielded a higher
percentage of DA neurons and a higher level of dopamine
secretion. One of the direct causes of the motor symptoms in
PD patients is the progressive depletion of dopamine supply
in striatum (Buttery and Barker, 2014). Dopamine replenish-
ment has been shown to alleviate the motor problems. For
example, levodopa—the drug that has been used in clinics
for years and shown good therapeutic effects in the first few
years of treatment, is the precursor to dopamine and can be
converted to dopamine once it enters the central nervous
system (Marsden and Parkes, 1976). Transplantation of fetal
ventral mesencephalon into the striatum of PD patients can
enhance dopamine levels and improve motor functions in
some patients (Olanow et al., 2003; Freed et al., 2001;
Lindvall et al., 1990). In the current study, although only few
TH-positive cells had survived by the end of the experiment
(11 weeks post-transplantation), it is possible that more
cells were surviving at earlier time points and the replen-
ishment of dopamine by the engrafted cells may have
accounted for the improved motor behavior. Another
possibility is that the engrafted cells had directly or
indirectly produced neurotrophic factors that could nourish
the endogenous DA neurons and enhance their functions.
GDNF is a well-studied factor that has a robust neurotrophic
effect on DA neurons (Lin et al., 1993). Astrocytes express
dopamine receptor D1 and upon activation by dopamine,
astrocytes may produce GDNF (Kuric et al., 2013) that isng motor behavior recovery in PD mice and in restoring TH signal
in vivo study. B: Ipsilateral rotations of PD mice transplanted with
lack) 4 weeks after 6-OH DA injection (one week before cell
mbers represented ipsilateral minus contralateral rotations. n = 9 in
nd n = 7 in buffer group. C: TH-positive neurons differentiated from
striatum. Bar = 20 μm. D: Representative pictures showing the TH
s contralateral counterpart. E: Relative TH signal abundance in the
part. n = 9 in iNSC-Lmx1a group; n = 9 in iNSC-GFP group; n = 8 in
F: Scatter plots showing the correlation between relative TH signal
ter one outlier was removed, ipsilateral turns negatively correlated
le bars: 20 μm (C) and 250 μm (D).
8 J. Wu et al.beneficial to the endogenous DA neurons. Another possible
effector is BDNF, which also has a protective role on DA
neurons (Spina et al., 1992; Hyman et al., 1991). Both NSCs
and mature neurons can synthesize BDNF (Blurton-Jones et
al., 2009; Conner et al., 1997; Legutko et al., 2001). In our
present work, the greater abundance of TH signals in
striatum at the axonal terminals of DA neurons may have
possibly resulted from these non-autonomous effects from
engrafted iNSCs.
In summary, this study for the first time showed that
induced neural stem cells directly converted from somatic
cells exerted therapeutic effect when transplanted into a
mouse PD model, and this effect may have possibly resulted
from iNSCs through a non-autonomous manner.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2014.10.004.
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